female patients who are currently pregnant history of severe allergic reaction to vaccines concomitant inherited immunodeficiency any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator s opinion, could compromise the subject s safety or put the study outcomes at undue risk. receive cytotoxic chemotherapy within 2 weeks prior to vaccination receive intravenous immunoglobulin (ivig) within 2 months prior to vaccination receive anti-cd20 and/or anti-cd19 monoclonal antibody therapy within 6 months prior to vaccination receive cellular therapy (e.g. car-t cells) within 12 months prior to vaccination history of allogeneic stem cell transplantation

female patients who are currently pregnant history of severe allergic reaction to vaccines concomitant inherited immunodeficiency any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator s opinion, could compromise the subject s safety or put the study outcomes at undue risk. receive cytotoxic chemotherapy within 2 weeks prior to vaccination receive intravenous immunoglobulin (ivig) within 2 months prior to vaccination receive anti-cd20 and/or anti-cd19 monoclonal antibody therapy within 6 months prior to vaccination receive cellular therapy (e.g. car-t cells) within 12 months prior to vaccination history of allogeneic stem cell transplantation